## IJPSR (2019), Volume 10, Issue 7



INTERNATIONAL JOURNAL



Received on 12 November 2018; received in revised form, 08 March 2019; accepted, 09 March 2019; published 01 July 2019

# COMPOUNDS FROM *TROPIDIA CURCULIOIDES* AS INDUCERS OF APOPTOSIS IN CANCER CELLS

N. Sarkar<sup>1</sup>, R. Verma<sup>2</sup>, A. Dixit<sup>2</sup> and S. Ghosal<sup>\*1</sup>

Centre for Plant and Environmental Biotechnology<sup>1</sup>, Amity Institute of Biotechnology, AUUP, Sector 125, Noida - 201313, Uttar Pradesh, India.

School of Biotechnology<sup>2</sup>, Jawaharlal Nehru University, New Delhi - 110067, Delhi, India.

### **Keywords:**

*Tropidia curculioides*, Anticancer activity, 4-hydroxybenzaldehyde, Bisphenol F, 3,5-dihydroxy-4methoxy benzoic acid, Annexin-FITC/PI staining assay

#### Correspondence to Author: Dr. Sabari Ghosal

Professor & Head, Centre for Plant and Environmental Biotechnology, Amity Institute of Biotechnology, AUUP, Sector 125, Noida - 201313, Uttar Pradesh, India.

**E-mail:** sabarighosal@gmail.com

ABSTRACT: Arunachal Pradesh (AP), the North-eastern state of India, is a natural habitat of 550 species of orchids including 37 species of medicinal importance. Though these plants are used extensively by locals for various ailments, very few scientific investigations have been conducted to establish their pharmacological potential. In the present study, we selected Tropidia curculioides, a relatively unexplored orchid to evaluate its cytotoxic potential. As any investigation has not been conducted to evaluate the cytotoxic potential of the extracts or compounds, we performed screening of the compounds, previously isolated by our group for cytotoxic activity against three cancer cells viz., MCF-7, A549, and SiHa cells. Interestingly, all three compounds exhibited  $IC_{50}$  in the range of 30-50  $\mu$ M. Further, we studied apoptosis inducing property and ROS mediated cell death with the most active compound. The result indicated that TcR-3, a gallic acid derivative possesses maximum activity with IC<sub>50</sub> of 34.26 µM against A549 cells. The cell proliferation assay and apoptosisinducing property measured by flow cytometry indicated that the compound has comparable activity to that of standard drug doxorubicin. Further, it was capable of inducing ROS-mediated cell death against A549 cells. Cell cytotoxicity of the compound was well within the permissible limit. The present study identified TcR-3 as a chemopreventive agent which could further be investigated for target-based activity.

**INTRODUCTION:** Orchids are known for their aesthetic and economic importance. However, few of them also possess enormous medicinal importance. Out of 550 species of orchids reported from Arunachal Pradesh (AP), 37 are of medicinal importance <sup>1</sup>. Though these plants are an integral part of the traditional system of medicine, hardly any investigation has been conducted to establish their pharmacological properties.

QUICK RESPONSE CODE		
	DOI: 10.13040/IJPSR.0975-8232.10(7).3428-33	
	The article can be accessed online on www.ijpsr.com	
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.10(7).3428-33		

*Tropidia curculioides* (Tc) Lindl. is a rare orchid mostly found in tropical and subtropical areas of AP  $^2$ . Though the genus *Tropidia* comprises nearly 30 species  $^3$ , only one species *T. curculioides* is found in Indian subcontinent. A decoction of the whole plant is used in the cold stage of malaria, and root decoction is used in acute cases of diarrhea  $^4$ . Besides, any scientific report on the evaluation of cytotoxic potential or any other activity is not available.

Modern medicinal approach to combat several lethal diseases depends on using a single molecule for a single target; however, several complex diseases, such as cancer could be treated in a cost-effective and preventive manner by multi-component preparations  $^{5}$ .

Some medicinal plant extracts and plant-derived compounds had exhibited significant efficiency to control the complex phenomenon of carcinogenesis through induction of apoptosis <sup>6, 7</sup>. Additionally, a number of orchids and purified compounds therein, showed prominent anti-proliferative activity<sup>8</sup>. Dendrowilol, isolated from the orchid Dendrobium williamsonii showed potent cytotoxic activity against cancer cells HL-60 with IC<sub>50</sub> of 4.4  $\mu$ M<sup>9</sup>. 5,7-dihydroxy-6,4-dimethoxyflavone Likewise. isolated from Brazilian orchid Miltonia flsavescens showed activity against NCI/ADR-RES ovary sarcoma cells at IC<sub>50</sub> of 2.6  $\mu$ g/mL<sup>10</sup>. In our previous study, we investigated three comparatively unexplored orchids of AP namely, Satyrium nepalense, Rhynchostylis retusa, and bioassay-guided Tropidia curculioides by fractionation for antimycobacterial, leishmanicidal and antibacterial activity.

The result demonstrated that the diethyl ether (Et<sub>2</sub>O) fraction of roots of Tc exhibited most potent antibacterial activity with MIC 125  $\mu g/ml;$ antimycobacterial activity 125 µg/ml (MIC); and leishmanicidal activity of 100  $\mu$ g/ml (IC<sub>50</sub>)<sup>11</sup>. To compounds, identify the marker column chromatography of Et<sub>2</sub>O fraction was conducted which resulted in the isolation of three compounds viz., 4-hydroxy benzaldehyde (TcR-1), 4,4'dihydroxydiphenylmethane (TcR-2) and 3.5dihydroxy-4-methoxy benzoic acid (TcR-3)<sup>12</sup> Fig. 1. Structure of the compounds was established by NMR and Mass spectral analysis. As any report on the anti-cancer potential of the compounds was not available, we thought of conducting the present investigation.



FIG. 1: CHEMICAL STRUCTURE OF COMPOUNDS (TcR-1, TcR-2, AND TcR-3) ISOLATED FROM *TROPIDIA CURCULIOIDES* 

## **MATERIALS AND METHODS:**

**Chemicals and Reagents:** General chemicals used in the study were of analytical grade. Reagents for mammalian cell culture *viz*. Dulbecco's Modified Eagle's Medium (DMEM), Fetal Bovine Serum (FBS), Penicillin-streptomycin solution and Trypsin-EDTA were obtained from Biological Industries, Israel. Doxorubicin (Dx), 3-(4,5-dimethylthiazol-2-yl)- 2, 5- diphenyltetrazolium bromide (MTT), FITC-Annexin V and propidium iodide (PI) and dimethyl sulfoxide (DMSO) and dichlorofluorescein-diacetate (DCFH-DA) were obtained from Sigma Aldrich Chemicals Co. (St. Louis, MO, USA).

**Cell Culture:** Cervical cancer cells SiHa; and Human embryonic kidney cells (HEK293) were procured from National Centre for Cell Science, Pune, India. Lung cancer cells A549 (ATCC No.CCL-185) and breast cancer cells MCF7 (ATCC No. HTB-22) were obtained from American Type Culture Collection, Manassas, VA USA. The cells were cultured in DMEM supplemented with FBS (10% v/v), 100 units/ml penicillin and 100 µg/ml streptomycin at 37 °C in a CO<sub>2</sub> incubator.

**Cell Proliferation Assay:** The MTT assay was used to measure viability on treated cells as described previously <sup>13</sup>. Briefly, the cancer cells of different origin (lung cancer, A549; cervical cancer, SiHa; and breast cancer, MCF7) were used for the assay. Normal cells HEK293 were used for cell cytotoxicity assay. Briefly, the cells were seeded at an initial density of  $5 \times 10^3$  cells/well/100 µL of DMEM supplemented with 10% FBS in a 96-well tissue culture plate and cultured in a CO<sub>2</sub> incubator for overnight at 37 °C. Subsequently, the medium was replaced with fresh medium, and different concentrations of the compounds (in triplicates) were added to the wells, keeping the final concentration of DMSO not exceeding 0.2%.

The cells treated with 0.2% DMSO (vehicle) were included as the control. After 48 h, MTT solution (5 mg/ml in PBS) was added to each well to make the final concentration of 0.5 mg/ml. It was further incubated for 3 h, the medium was aspirated, and 100  $\mu$ L of DMSO was added to solubilize the formazan crystals. Absorbance at 570 nm was recorded using a microplate reader. The experiment was performed in triplicates, and the results were expressed in mean ± S.D. Percentage cytotoxicity was calculated concerning MTT absorbance of the vehicle-treated cells. Flow Cytometric Analysis: To understand the mode of cell death (necrotic/apoptotic), dual staining with FITC-conjugated Annexin V and PI was carried out as described previously. Briefly, the cells were treated with different dilutions of TcR-3 and were harvested by trypsinization. After 48 h, the cells were subjected to labeling with fluorochrome-conjugated antibodies. The treated cells were resuspended in 100 µl of Annexin binding buffer (10 mM Hepes-NaOH, pH 7.4; 140 mM NaCl; 2.5 mM CaCl<sub>2</sub>), followed by addition of 5 µl of FITC-conjugated annexin-V (0.02 µg/µl) and PI (5 ng/µl) in each well.

The incubation was continued for 10 min, and the binding buffer (400 µl) was added to the cells followed by flow cytometric analysis (FACS caliber, Beckton-Dickinson Immunocytometry Excitation and system. USA). emission wavelengths for FITC-Annexin V were 485 nm and 535 nm respectively and for PI were 535 nm and 620 nm respectively. The FACS data were analyzed using Flowjo software, and different cell populations (necrotic, primary apoptotic and late apoptotic) were determined  $^{14}$ .

**Free Radical Generation Analysis:** To understand whether TcR-3 caused apoptosis due to ROS production, flow cytometric analysis was carried out using dichlorofluorescein- diacetate (DCFH- DA), as a fluorescent probe. Fluorescence could be detected only if the probe was oxidized to dichlorofluorescein (DCF) by ROS inside the cell <sup>15</sup>. The test compound treated cells were harvested by trypsinization for 48 h then it was washed once with PBS, resuspended in 0.5ml of PBS followed by the addition of 2'7'-dichlorodihydrofluorescein diacetate (DCFH-DA, 10 $\mu$ M). The cells were incubated for 15 min and were analyzed by flow cytometry using FACS Calibur, where excitation and emission frequency was set at 485 nm and 530 nm, respectively <sup>16</sup>. Here, vehicle and doxorubicintreated cells were taken as negative and positive controls.

**Statistical Analysis:** All experiments were carried out in triplicates, and the results were expressed as the mean  $\pm$  SD value from at least three independent experiments. Statistical analyses were carried out using GraphPad software (Chicago, USA).

**RESULTS:** Three compounds isolated from the bioactive  $Et_2O$  fraction of Tc were investigated by MTT based cell proliferation assay against MCF-7, A549, and SiHa cells. The compounds were characterized as 4-hydroxy benzaldehyde (TcR-1), 4,4'-dihydroxydiphenylmethane (TcR-2) and 3,5-dihydroxy-4-methoxy benzoic acid (TcR-3) and the result has been summarized in **Table 1**.



FIG. 2: ANALYSIS OF CYTOTOXIC ACTIVITY OF TC COMPOUNDS. SiHa and MCF7 cells were treated with different concentrations of Tc compounds for 48 h, and cell viability was analyzed by MTT reduction assay. HEK293 cells treated with the same concentrations of the three compounds were included as a normal control cell. Percentage cytotoxicity and significance levels are calculated concerning vehicle-treated cells. <sup>a</sup>,  $p \le 0.001$ ; <sup>b</sup>,  $p \le 0.005$ ; <sup>c</sup>,  $p \le 0.01$ ; <sup>e</sup>,  $p \le 0.05$ .

Doxorubicin was used as a positive control. The result showed the promising antiproliferative activity of the compounds lying in the range of 30-50  $\mu$ M (IC<sub>50</sub>) as expressed in **Fig. 2**. The compound TcR-3 showed maximum activity against A549 cells with IC<sub>50</sub> 34.26  $\mu$ M, followed by cervical (SiHa) and breast cancer (MCF7) with IC<sub>50</sub> 36.82 and 43.75  $\mu$ M respectively. Rest two compounds exhibited moderate cytotoxicity. Further, to evaluate cell cytotoxicity of the compounds MTT assay was conducted against normal HEK293 cells at the experimental concentrations of each compound. The healthy cells exhibited cell cytotoxicity well within the permissible limit.

TABLE 1: CYTOTOXICITY OF COMPOUNDS EXPRESSED IN  $IC_{50}$  (µM) VALUES AGAINST DIFFERENT CANCER CELL LINE

Compounds	A549	SiHa	MCF7
TcR-1	49.63±1.753	45.66±1.461	43.6±5.502
TcR-2	$45.02 \pm 2.329$	$41.8 \pm 0.908$	37.19±6.046
TcR-3	$34.26 \pm 2.384$	36.82±1.362	43.75±5.244
Doxorubicin	6.69	0.41	1.7

To understand the mode of cell death (necrosis or apoptosis), dual staining with FITC-conjugated Annexin V and PI was performed at  $IC_{50}$  concentration of TcR-3 against A549 cells **Fig. 3**. As evident from the figure, TcR-3 predominantly induced apoptotic cell death. The total number of late and early apoptotic cells was comparable to that observed in doxorubicin-treated cells.



FIG. 3: ANNEXIN-PI STAINING TO DETERMINE THE MODE OF CELL DEATH BY TCR-3. The A549 cells treated with IC<sub>50</sub> dose of TCR-3 for 48 h, were subjected to dual staining with FITC-Annexin V and PI and analyzed by FACS. DMSO-treated cells (VC) were included as negative control whereas doxorubicintreated cells (DX) were included as positive control. A population of necrotic (Annexin V-/PI+), primary apoptotic (Annexin V+/PI-) and late apoptotic (Annexin V+/PI+) was analyzed Flowjo software. Significance levels are calculated concerning vehicle-treated cells. a, p $\leq$ 0.001; b, p $\leq$ 0.005; c, p $\leq$ 0.01; d, p $\leq$ 0.01; e, p $\leq$ 0.05.

It is well established that any kind of interruption in the redox state of a cell affects cell health and increases ROS production resulting in cell death. Therefore, ROS levels in TcR-3 treated A549 cells were analyzed to see if apoptosis is ROS-mediated. As evident from **Fig. 4**, significant increase ( $p \le 0.01$ ) in the DCF fluorescence, indicative of ROS production, was observed in TcR-3 treated cells as compared to vehicle-treated cells. The increase in ROS production was comparable to that observed with doxorubicin, the positive control.



FIG. 4: DETERMINATION OF ROS PRODUCTION BY DCFH-DA STAINING. The A549 cells treated with the IC<sub>50</sub> dose of TcR-3 for 48 h and subjected to staining with DCFH-DA. DMSO-treated cells (VC) were included as negative control whereas doxorubicin-treated cells (Dx) were included as positive control. DCF Fluorescence events were analyzed using Flow Jo Software. The Figure represents mean  $\pm$  SD of three independent experiments performed in triplicate. Significance levels are determined concerning vehicle-treated cells. 'd'= p≤0.01.

**DISCUSSION:** As evident from the results, all compounds demonstrated dose-dependent growth inhibition on different cancer cells. The compound 4-hydroxy benzaldehyde TcR-1 exhibited moderate cytotoxic activity against all cancer cells. It is worth mentioning here that recently a case of tongue cancer and two cases of lung cancer have been treated with successfully 4-hydroxybenzaldehyde after a surgical operation <sup>17, 18</sup>. The compound TcR-2 with common name Bisphenol F or 4,4'-dihydroxydiphenylmethane also exhibited good cytotoxic activity towards breast cancer cells with IC<sub>50</sub> 37.19  $\mu$ M and moderate activity against cervical and lung cancer cells (IC<sub>50</sub> in the range of 41-45 µM). A chemically similar compound, Bisphenol A-induced apoptosis against human promyelocytic leukemia (HL-60) cells <sup>19</sup>. The third compound TcR-3, a gallic acid derivative 3.5dihydroxy-4-methoxy benzoic acid exhibited maximum cytotoxic potency against A549, lung cancer cells with  $IC_{50}$  34.26 µM in our study. In cervical (SiHa) and breast cancer (MCF7), it also showed significant activity in the range 36-43 µM  $(IC_{50})$ . Our results are in agreement with earlier reports wherein the parent phenolic compound gallic acid has shown cytotoxic activity against a variety of cancers <sup>20, 21</sup>

However, comparative analysis of  $IC_{50}$  of TcR-3 and gallic acid showed that the former compound is more effective. Comparative analysis demonstrated that TcR-3 exhibited  $IC_{50}$  of 36 µM against SiHa cells whereas, gallic acid showed  $IC_{50}$  of 80 µM against HeLa <sup>22</sup>. In a similar note, TcR-3 showed almost half activity than the parent gallic acid (~60 µM,  $IC_{50}$ ) as reported earlier <sup>23</sup> against A549 cells. Since cell cytotoxicity of TcR-3 was negligible it could also serve in combination with existing chemotherapeutic agents.

It is well established that almost all cancer cells continue to proliferate by evading apoptosis and most of the cytotoxic compounds promote apoptosis in cancer cells. To establish if the cytotoxic effect brought about by TcR-3 is due to induction of apoptosis, Annexin V-PI staining of the treated cells was carried out. When a compound affects the cell adversely, the damage on the cell membrane results in the externalization of phosphatidylserine from the inner side of the plasma membrane to the cell surface, thus allowing annexin V binding to phosphatidyl serine. An increase in FITC-Annexin V stained cell population clearly shows induction of apoptosis (shown in the figure as early apoptotic cell population).

Disruption of membrane integrity allows PI uptake which then binds to DNA or RNA during late apoptosis. It is thus clear that TcR-3 can induce apoptosis. Though cancer cells have increased ROS levels, they adopt several mechanisms to counter the increased ROS levels and hence evade cell death. An increase in ROS production by the cytotoxic agents is one of the mechanisms by which they induce cell death. Here, the integrity of the mitochondrial membrane plays an important role in cell health. Depolarization of mitochondrial membrane is caused mostly due to enhanced ROS production which is associated with apoptosis <sup>24</sup>. The increased ROS production in TcR-3-treated cells as indicated by DCF fluorescence, suggests that TcR-3 induces apoptosis through ROS mediated route.

**CONCLUSION:** Thus, the present study indicates that the cytotoxic potential of TcR-3 is due to ROS-mediated apoptosis. These findings can further be validated by *in-vivo* studies to establish its chemotherapeutic potential.

ACKNOWLEDGEMENT: Authors acknowledge Dr. A. K. Chauhan, Founder President, Amity University, for his continuous motivation and encouragement. AD acknowledges the financial support from the University with Potential for Excellence grant (UPE-II) from JNU, New Delhi. This work was financially supported by the Department of Biotechnology, Government of India (DBT Sanction Order No: BT/332/NE/TBP/ 2012).

**CONFLICT OF INTEREST:** None of the authors have declared any conflict of interest from being named as an author on the above manuscript.

## **REFERENCES:**

- 1. Sarkar N, Saha B, Singh S and Ghosal S: Tropidia Curculioides: Secondary metabolites and derivatives with antimycobacterial and leishmanicidal activity. Phcog Mag 2018; 14(19): 535-8.
- 2. Chakraborty R, Deb B, Devanna N and Sena S: North-East India an ethnic storehouse of unexplored medicinal plants. J Nat Prod Plant Resour 2012; 291: 143-52.
- 3. Rao AN: Medicinal orchid wealth of Arunachal Pradesh. Indian Medicinal Plants of Conservation Concern (Newsletter of ENVIS Node, Foundation for Revitalisation of Local Health Traditions, Bangalore) 2004; 1: 1-5.
- 4. Joshi G, Tewari LM, Lohani N, Upreti K, Jalal JS and Tewari G: Diversity of orchids on Uttarakhand and their conservation strategy with special reference to their medicinal importance. Rep Opin 2009; 1(3): 47-52.
- Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A and Ashraf SS: Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology 2015; 35: S276-S304.
- 6. Thakur VS, Deb G, Babcook MA and Gupta S: Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. The AAPS J 2014; 16(1): 151-63.
- Iqbal J, Abbasi BA, Mahmood T, Kanwal S, Ali B, Shah SA and Khalil AT: Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed 2017; 7(12): 1129-50.
- Laurentius H, Nugroho R, Pratiwi R, Susandarini E, Wardoyo O, Megawati S and Handayani O: Isolation of Bioactive Compounds From Two Orchid Species And Preliminary Test Of Their Cytotoxicity Against T47D Breast Cancer Cells. Int J Pharmacognosy and Phytochem. Res 2016; 8(1): 150-55.
- 9. Yang M, Zhang Y, Chen L and Chen Y: A new (propylphenyl) bibenzyl derivative from *Dendrobium williamsonii*. Nat Prod Res 2018; 32(14): 1699-05.
- 10. Porte LF, Santin SM, Chiavelli LU, Silva CC, Faria TJ, Faria RT, Ruiz AL, Carvalho JE and Pomini AM: Bioguided identification of antifungal and antiproliferative compounds from the Brazilian orchid *Miltonia flavescens* Lindl. Naturforsch 2014; 69(1-2): 46-52.
- 11. Bhatnagar M, Sarkar N, Gandharv N, Apang O, Singh S and Ghosal S: Evaluation of antimycobacterial, leishmanicidal and antibacterial activity of three medicinal orchids of Arunachal Pradesh. India. BMC Complement Altern 2017; 17: 379-6.

- Sarkar N, Avashti AS and Ghosal S: Bioactive fraction of Tropidia curculioides, a rare orchid of Arunachal Pradesh, India: Phytochemical profile and marker compounds. Asian J Pharm Clin Res 2018; 11(5): 1-7.
- Jaudan, A, Sharma S, Malek NS and Dixit A: Induction of apoptosis by pinostrobin in human cervical cancer cells: Possible mechanism of action. PloS one 2018; 13(2): e0191523.
- 14. Lee JM, Gordon N, Trepel JB, Lee MJ, Yu M and Kohn EC: Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. J Transl Med 2015; 13: 239-10.
- 15. Rothe G and Valet G: Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'-dichlorofluorescin. J Leukoc Biol 1990; 47(5): 440-48.
- 16. Mahfouz R, Sharma R, Lackner J, Aziz N and Agarwal A: Evaluation of chemiluminescence and flow cytometry as tools in assessing production of hydrogen peroxide and superoxide anion in human spermatozoa. Fertil Steril 2009; 92(2): 819-27.
- Okazaki K: Two Cases of Lung Cancer Successfully Treated with 4-Hydroxybenzaldehyde after Surgical Operations. J Lung Cancer Diagn Treat 2017; 2: 116.

- Okazaki K: A Case of Tongue Cancer Successfully Treated With 4-Hydroxybenzaldehyde after A Surgical Operation. Res J Oncol 2017; 1: 9.
- 19. Terasaka H, Kadoma Y, Sakagami H and Fujisawa S: Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells. Anticancer Res 2005; 25(3B): 2241-48.
- Subramanian AP, John AA, Vellayappan MV, Balaji A, Jaganathan SK, Supriyanto E and Yusof M: Gallic acid: prospects and molecular mechanisms of its anticancer activity. RSC Adv 2015; 5: 35608-21.
- 21. Bharti B, Sharma N and Kakkar R: Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv 2015; 5: 27540-57.
- 22. You BR, Moon JH, Han HY and Park WH: Gallic acid inhibits the growth of HeLa cervical cancer cells *via* apoptosis and/or necrosis. Food Chem Toxicol 2010; 48(5): 1334-40.
- Ohno Y, Fukuda K, Takemura G, Toyota M, Watanabe M, Yasuda N, Xinbin Q, Maruyama R, Akao S, Gotou K, Fujiwara T and Fujiwara H: Induction of apoptosis by Gallic acid in lung cancer cells. Anticancer Drugs 1999; 10(9): 845-51.
- 24. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 2011; 15(22): 2922-33.

#### How to cite this article:

Sarkar N, Verma R, Dixit A and Ghosal S: Compounds from *Tropidia curculioides* as inducers of apoptosis in cancer cells. Int J Pharm Sci & Res 2019; 10(7): 3428-33. doi: 10.13040/IJPSR.0975-8232.10(7).3428-33.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to Android OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Play store)